← Eichor
Study identifier: NCT06949579 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.

Condition: High Myopia  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included. 600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset. Besides the standard of care, blood samples will be collected. All data collected will be stored in an onlie Castor database

This description comes directly from the study's public registry record.

Talk to the study team

Francine Behar-Cohen, MD, PhD  ·  06 60 97 44 19  ·  francine.cohen@aphp.fr

Valérie PLENCE, Msc  ·  01 58 41 11 78  ·  valerie.plence-fauroux@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Cochin HospitalParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06949579